Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2008;51:676-681
Published online before print January 22, 2008, doi: 10.1161/HYPERTENSIONAHA.107.101493
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
51/3/676    most recent
HYPERTENSIONAHA.107.101493v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muller, D. N.
Right arrow Articles by Hilgers, K. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muller, D. N.
Right arrow Articles by Hilgers, K. F.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Other hypertension
Right arrow Other Treatment

(Hypertension. 2008;51:676.)
© 2008 American Heart Association, Inc.


Original Articles

(Pro)Renin Receptor Peptide Inhibitor "Handle-Region" Peptide Does Not Affect Hypertensive Nephrosclerosis in Goldblatt Rats

Dominik N. Muller; Bernd Klanke; Sandra Feldt; Nada Cordasic; Andrea Hartner; Roland E. Schmieder; Friedrich C. Luft; Karl F. Hilgers

From the Medical Faculty of the Charité (D.N.M., S.F., F.C.L.), Experimental and Clinical Research Center, Franz Volhard Clinic, and HELIOS Klinikum Berlin-Buch, and Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany; and the Department of Nephrology and Hypertension (B.K., N.C., R.E.S., K.F.H.) and Childrens’ Hospital (A.H.), University of Erlangen-Nuremberg, Erlangen, Germany.

Correspondence to Karl F. Hilgers, Department of Nephrology and Hypertension, University of Erlangen-Nuremberg, Loschgestrasse 8, 91054 Erlangen, Germany. E-mail karl.hilgers{at}rzmail.uni-erlangen.de

The (pro)renin receptor [(P)RR], a new component the renin-angiotensin system, was cloned recently. The (P)RR promotes direct mitogen-activated protein kinase signaling and nonproteolytic prorenin activation. We investigated the role of a (P)RR blocker, a peptide consisting of 10 amino acids from the prorenin prosegment called the "handle-region" peptide (HRP), on target organ damage in renovascular hypertensive 2-kidney, 1-clip (2K1C) rats. Vehicle-treated 2K1C rats were compared with HRP-treated 2K1C rats (3.5 µg/kg per day) and sham-operated controls. Vehicle-treated 2K1C rats developed hypertension (186±17 mm Hg), cardiac hypertrophy (3.16±0.16 mg/g), renal inflammation, fibrosis, vascular, and tubular damage. Chronic HRP treatment did not affect blood pressure (194±15 mm Hg), cardiac hypertrophy (2.97±0.11 mg/g), or renal damage. Furthermore, we investigated the renal renin and (P)RR expression. The clipped kidney of 2K1C and HRP-treated 2K1C rats showed a higher renin expression and juxtaglomerular index compared with sham-operated kidneys. The unclipped kidney showed suppressed renin expression. In contrast, (P)RR mRNA expression was not altered in any group. Plasma renin activity and aldosterone were increased in 2K1C rats compared with sham controls. HRP-treated 2K1C rats tended to lower plasma renin activity but showed similar aldosterone levels as vehicle-treated 2K1C rats. Our results indicate that blockade of the (P)RR with HRP does not improve target organ damage in renovascular hypertensive rats.


Key Words: renin • (pro)renin receptor • HRP • target organ damage • angiotensin • renovascular hypertension




This article has been cited by other articles:


Home page
DiabetesHome page
S. Satofuka, A. Ichihara, N. Nagai, K. Noda, Y. Ozawa, A. Fukamizu, K. Tsubota, H. Itoh, Y. Oike, and S. Ishida
(Pro)renin Receptor-Mediated Signal Transduction and Tissue Renin-Angiotensin System Contribute to Diabetes-Induced Retinal Inflammation
Diabetes, July 1, 2009; 58(7): 1625 - 1633.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Mercure, G. Prescott, M.-J. Lacombe, D. W. Silversides, and T. L. Reudelhuber
Chronic Increases in Circulating Prorenin Are not Associated With Renal or Cardiac Pathologies
Hypertension, June 1, 2009; 53(6): 1062 - 1069.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
J. L. Wilkinson-Berka
Prorenin and the (Pro)renin Receptor in Ocular Pathology
Am. J. Pathol., December 1, 2008; 173(6): 1591 - 1594.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. Susic, X. Zhou, E. D. Frohlich, H. Lippton, and M. Knight
Cardiovascular effects of prorenin blockade in genetically spontaneously hypertensive rats on normal and high-salt diet
Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1117 - H1121.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. J. Brown
Aliskiren
Circulation, August 12, 2008; 118(7): 773 - 784.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
G. Nguyen and A. H. J. Danser
Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents
Exp Physiol, May 1, 2008; 93(5): 557 - 563.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
D. J. Campbell
Critical Review of Prorenin and (Pro)renin Receptor Research
Hypertension, May 1, 2008; 51(5): 1259 - 1264.
[Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
F. C Luft
The Bothrops legacy: Vasoactive peptides from Brazil
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2008; 9(1): 57 - 64.
[PDF]